Updated results from a subgroup analysis of a phase 1/2 trial showed that ifinatamab deruxtecan (I-DXd) continues to demonstrate durable responses in patients with heavily pretreated advanced small cell lung cancer.

This article summarized the latest R&D progress of Somatostatin, the Mechanism of Action for Somatostatin, and the drug target R&D trends for Somatostatin.

CDK5, or cyclin-dependent kinase 5, is a crucial enzyme found in the human body that plays a significant role in various physiological processes.

This article summarized the latest R&D progress of Silodosin, the Mechanism of Action for Silodosin, and the drug target R&D trends for Silodosin.

Bristol Myers Squibb's experimental LPA1 Antagonist showed promising results in reducing the rate of lung function decline in the Progressive Pulmonary Fibrosis group in a phase 2 clinical trial.

This article summarized the latest R&D progress of Secretin, the Mechanism of Action for Secretin, and the drug target R&D trends for Secretin.

CDK4, or cyclin-dependent kinase 4, is a crucial protein involved in cell cycle regulation in the human body.

This article summarized the latest R&D progress of Riluzole, the Mechanism of Action for Riluzole, and the drug target R&D trends for Riluzole.

Promising clinical responses were observed in TROPION-Lung04's Phase 1b Trial with a combination of Datopotamab Deruxtecan and Durvalumab with Non-Small Cell Lung Cancer.

This article summarized the latest R&D progress of Ranolazine, the Mechanism of Action for Ranolazine, and the drug target R&D trends for Ranolazine.

CDK2, or cyclin-dependent kinase 2, is a crucial protein involved in cell cycle regulation in the human body.

This article summarized the latest R&D progress of Ramelteon, the Mechanism of Action for Ramelteon, and the drug target R&D trends for Ramelteon.